Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Vobramitamab Duocarmazine |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Vobramitamab Duocarmazine
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Elimusertib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Elimusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Gartisertib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Gartisertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Selumetinib Sulfate |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Selumetinib Sulfate
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Tunlametinib |
DNA Damage Response Inhibitor | Solid Tumour | ||
|
Molecule
Tunlametinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
||||
Ipatasertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Ipatasertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Capivasertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Capivasertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Afuresertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Afuresertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
MK-2206 (AKT Inhibitor) |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
MK-2206 (AKT Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Uprosertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Uprosertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Triciribine |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Triciribine
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Vibostolimab |
TIGIT Inhibitor | Solid Tumour | ||
|
Molecule
Vibostolimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
||||
Vobramitamab DuocarmazineTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
ElimusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
GartisertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
Selumetinib SulfateTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
TunlametinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor |
|
IpatasertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
CapivasertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
AfuresertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
MK-2206 (AKT Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
UprosertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
TriciribineTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
VibostolimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Solid Tumour
Drug Class / Mechanism
TIGIT Inhibitor |
|